Organogenesis (NASDAQ:ORGO) Trading 3.5% Higher – Here’s Why

Organogenesis Holdings Inc. (NASDAQ:ORGO)’s stock price was up 3.5% on Tuesday . The stock traded as high as $5.08 and last traded at $5.15. Approximately 148,169 shares traded hands during trading, a decline of 86% from the average daily volume of 1,070,616 shares. The stock had previously closed at $4.97.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley increased their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th.

Organogenesis Stock Performance

The firm has a market capitalization of $643.02 million, a PE ratio of -84.50 and a beta of 1.66. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The business’s 50 day simple moving average is $3.97 and its two-hundred day simple moving average is $3.47.

Insider Activity at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the sale, the director now directly owns 166,879 shares in the company, valued at $851,082.90. The trade was a 13.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 36.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Captrust Financial Advisors bought a new stake in shares of Organogenesis during the third quarter worth $36,000. Virtu Financial LLC purchased a new position in shares of Organogenesis during the fourth quarter worth approximately $38,000. Intech Investment Management LLC purchased a new stake in shares of Organogenesis in the third quarter valued at approximately $43,000. Palumbo Wealth Management LLC bought a new position in Organogenesis in the fourth quarter worth approximately $65,000. Finally, ProShare Advisors LLC raised its position in Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock valued at $65,000 after purchasing an additional 6,689 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.